Ken Griffin Opgen Inc Transaction History

Citadel Advisors LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.39 - $78.8 $33,444 - $6.76 Million	85,754 Added 570.97%	100,773 $29,000
Q2 2022 Aug 15, 2022	BUY	$0.32 - $0.79 $4,806 - $11,865	15,019 New	15,019 $8,000
Q1 2022 May 16, 2022	SELL	$0.72 - $1.11 $82,307 - $126,890	-114,316 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.0 - $2.94 $57,491 - $169,023	57,491 Added 101.17%	114,316 $114,000
Q3 2021 Nov 15, 2021	BUY	$2.18 - $3.58 $39,436 - $64,762	18,090 Added 46.7%	56,825 $164,000
Q2 2021 Aug 16, 2021	SELL	$1.95 - $2.8 $67,356 - $96,717	-34,542 Reduced 47.14%	38,735 $87,000
Q1 2021 May 17, 2021	BUY	$1.8 - $3.55 $131,898 - $260,133	73,277 New	73,277 $183,000
Q4 2020 Feb 16, 2021	SELL	$1.7 - $2.47 $30,243 - $43,941	-17,790 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$1.98 - $3.37 $40,588 - $69,081	-20,499 Reduced 53.54%	17,790 $38,000
Q2 2020 Aug 14, 2020	BUY	$1.88 - $2.59 $71,983 - $99,168	38,289 New	38,289 $78,000
Q1 2020 May 15, 2020	SELL	$1.14 - $4.04 $18,520 - $65,633	-16,246 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$1.02 - $7.18 $16,570 - $116,646	16,246 New	16,246 $18,000

Ticker OPGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 53,698,500
Market Cap $41.9M
Description
OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants o...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.